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Abstract
Background: The aim of this study was to explore whether early goal-directed therapy (EGDT) was associated with
a lower mortality rate in comparison to usual care in patients with severe sepsis and septic shock.
Methods: PubMed, EMBASE, Cochrane library and a Chinese database (SinoMed) were searched systematically to identify
randomized controlled trials (RCTs) comparing standard EGDT with usual care in resuscitation of patients with severe sepsis
and septic shock and the search time could date back to the publication of the study by Rivers in 2001. The study
selection, data extraction and methodological evaluation were performed by two investigators independently. The primary
outcome was all-cause mortality. The present meta-analysis had been registered in PROSPERO (CRD42015017667).
Results: Our meta-analysis identified 6 studies and enrolling 4336 patients. There was no significant difference in mortality
between the two groups, and the pooled odds ratio (OR) was 0.83 (95 % confident interval, CI, 0.64–1.08) with significant
heterogeneity (p= 0.02, I2 = 64 %). However, the pooled OR of 3 multicenter RCTs was 1.03 (95 % CI, 0.89–1.21) with no
heterogeneity (p= 0.78, I2 = 0 %). The effects of EGDT on length of stay in the emergency department and intensive care
unit were uncertain, and there was no effect of EGDT on hospital length of stay. There were no differences of mechanical
ventilation rate and renal replacement therapy rate between the two groups, and patients in the EGDT group were more
admitted in ICU than patients in the control group. During the early 6-h intervention period, patients in the EGDT group
received more intravenous fluids, had a higher vasopressor usage rate, higher dobutamine usage rate and higher blood
transfusion rate, than patients in the control group. Finally, there was no difference in the incidence of adverse events
between the two groups, and the pooled OR was 1.06 (95%CI 0.80–1.39) with moderate heterogeneity (I2 = 62 %, p= 0.07).
Discussion: Our meta-analysis showed that the application of EGDT was not associated with lower mortality rate currently.
However it does not mean that it is useless of EGDT in patients with sever sepsis and septic shock. On the contrary, there
was no difference in mortality rate between the two groups may be due to the improvement of therapeutic strategies in
these patients. And the results may be related to the different compliance rate of EGDT resuscitation bundle.
Conclusions: The current evidence does not support the significant advantage of Early goal-directed therapy (EGDT) in the
resuscitation of patients with severe sepsis and septic shock.
Background
Sepsis, especially severe sepsis and septic shock are associ-
ated with a high rate of death and complications. It has
been reported that the annual incidence of severe sepsis
and septic shock in the United States is up to 300 cases per
100,000 people [1–3]. Despite the advances in the therapy
of severe sepsis and septic shock, the mortality of these pa-
tients remains high, ranging from 20 % to 50 % [4–6]. In
2001, a randomized, non-blinded, controlled trial con-
ducted by Rivers reported that patients with severe sepsis
and septic shock presenting to the emergency department
had a lower mortality rate, if they received a specific 6 h re-
suscitation bundle of early-goal directed therapy (EGDT),
and the absolute risk reduction was 16 % [7]. Therefore,
EGDT was recommended by the 2004, 2008 and 2012
surviving sepsis campaigning (SSC) guidelines [8–10].
Meanwhile, several observational studies also found the
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survival benefit of standard EGDT or modified EGDT in
comparison to usual care [11–29]. However, the effect of
EGDT was questioned in three multicenter randomized
controlled trials, namely ProCESS, ARISE and ProMISe.
The authors reported that EGDT did not reduce the mor-
tality rate of patients with severe sepsis and septic shock as
compared with usual care [6, 30, 31]. In a meta-analysis,
Gu reported that EGDT significantly reduces the overall
mortality of patients with sepsis. However, several limita-
tions of this study should be noted: firstly, the newest stud-
ies of ARISE and ProMISe study were not included;
secondly, the included studies in this meta-analysis were
published between 1992 and 2014, during which time the
standard care of sepsis as well as the definition of sepsis
had changed a lot; Thirdly, this meta-analysis ignored the
fact that the pooled results of China-centric studies were
significantly different from the pooled results of America
and Australia-centric studies; Finally, several studies in-
cluded in this meta-analysis did not meet the inclusion cri-
teria (one was not a RCT but a before-and-after study; one
included patients with systemic inflammatory response syn-
drome not sepsis and one evaluated modified EGDT not
standard EGDT) [32]. The objective of our study was to
systematically evaluate the effect of EGDT on patients with
severe sepsis and septic shock.
Methods
We had registered the present meta-analysis protocol in
PROSPERO (http://www.crd.york.ac.uk/PROSPERO/;
CRD42015017667). Our meta-analysis was conducted
and reported based on The Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [33].
Data sources
The following databases: PubMed, EMBASE, the
Cochrane library, and a Chinese database (SinoMed)
were searched systematically to identify eligible stud-
ies, which were published since the publication of the
study by Rivers in 2001 [7]. The search process of
PubMed was showed in Additional file 1. Additionally,
the bibliography of each relevant study was also exam-
ined to limit the potential publication bias. The last
update search on 5 April 2015 and there was no lan-
guage restriction.
Study selection and data extraction
Inclusion criteria (Patient, Intervention, Comparison,
Outcome, Study design)
Patients
Patients with severe sepsis or septic shock were included.
And the diagnosis of severe sepsis and septic shock was
made according to appropriate guidelines [34, 35].
Interventions
Standard EGDT
The standard EGDT was defined in the SSC guideline
including the central venous pressure (CVP) should
achieve 8 to 12 mmHg, mean arterial pressure (MAP)
should achieve 65 to 90 mmHg, urine output should
achieve 0.5 ml/kg/h or more, and central venous oxygen
saturation (ScvO2) should achieve 70 % or above within
the first 6 h of interventions [8].
Comparison
Usual care
The usual care was defined as conventional treatments
which were at the discretion of the clinicians.
Outcomes
The primary endpoint was all-cause mortality. If several
mortality rates were reported in one study, we preferred
to use the primary one. The secondary endpoints in-
cluded: the length of stay in emergency department
(ED), intensive care unit (ICU) and hospital; mechanical
ventilation rate, renal replacement therapy rate and ICU
admission rate; the intravenous fluids volume, vasopres-
sor use rate, dobutamine use rate, blood transfusion rate
in the first 6 h, between 6 and 72 h and between 0 and
72 h; the incidence of adverse events.
Study design
Randomized controlled trials (RCTs)
The complete processes of study selection and data ex-
traction were conducted by two investigators independ-
ently. The study selection was performed in three phases.
Firstly, two investigators independently screened the titles
and abstracts of all search results, then removed appar-
ently irrelevant studies, and imported those potentially eli-
gible studies into the Endnote; Secondly, the duplicated
studies were excluded; Thirdly, the remaining articles were
read in full text. Meanwhile, the following data were ex-
tracted from each eligible study using a pre-defined data
extraction sheet: the first author, year of publication, char-
acteristics of patients in the intervention and control
group, characteristics of resuscitation strategies in the
intervention and control group, mortality rate at different
follow-up time, other secondary outcome endpoints and
items for quality evaluation. Any discrepancy was resolved
by discussion with a third investigator.
Quality assessment
The methodological qualities of all included studies
were assessed by two investigators independently using
the Cochrane risk of bias tool. All eligible studies were
judged to be “high”, “unclear”, or “low” risk of bias
based on the following domains: random sequence gen-
eration; allocation concealment; blinding of patients
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and personnel; incomplete outcome data; selective out-
come reporting; other bias. Any one or more of the
above domains were considered to be at high risk of
bias, and then the study would be judged to be at high
risk of bias [36, 37]. Only when all key domains were
considered to be at low risk of bias, would be the study
judged to be at low risk of bias. In other cases, the risks
of bias were judged to be unclear [36, 37].
Data analysis
The primary endpoint was all-cause mortality. We prefer
to use all-cause mortality which was the primary end-
point in individual study. The metrics of odds ratio (OR)
and weighted mean difference (WMD) were used to ana-
lysis dichotomous variables and continuous variables
separately. Heterogeneity between studies was assessed
qualitatively using the Mantel-Haenszel chi-square test
and quantitatively using the I 2 statistics [38, 39]. When
P ≤ 0.1 or I2 ≥ 50 %, there was significant heterogeneity
between included studies, and random-effect model was
used, otherwise the fixed-effect model was used [40].
The publication bias was evaluated using funnel plot
and Egger’s test [41].
Post hoc subgroup analysis
ProCESS, ARISE and ProMISe are published recently
and are consistent in study design [6, 30, 31]. Thus, we
pooled the primary and secondary endpoints repeatedly
based on the above three studies, when required data
were available.
In actually, the results of a meta-analysis are the ac-
cumulation of results of all eligible studies. Therefore,
it is vulnerable to random errors deriving from sparse
data and repetitive testing of accumulated data [42]. In
addition, enough sample size is necessary for a meta-
analysis. Trial sequential analysis (TSA) is the best
available approach to calculate the optimal required
information size (meta-analysis sample size) for a meta-
analysis [43]. TSA was performed in our meta-analysis
based on the average baseline mortality rate of control
group, a relative risk reduction of 20 [6, 30, 31], 80 of
power, and a type I error of 5 %. The random errors
adjusted monitoring boundaries were constructed to de-
termine whether new clinical trials were still required to
confirm the present conclusion [43–44]. Statistical analyses
were performed on Revman 5.2.5, STATA (SERIAL NO.
40120519635) and TSAV.0.9 β (http://www.ctu.dk/tsa/).
Results
After excluding the reduplicative, non-relevant studies
and other studies that did not meet our inclusion cri-
teria, 6 studies comparing standard EGDT with usual
care in patients with severe sepsis and septic shock were
eligible [6, 7, 30, 31, 45, 46]. The flow chart of literature
selection and corresponding exclusion reasons are sum-
marized in Fig. 1. Among the included studies, 2 studies
from China [45, 46], 2 studies from the USA [6, 7], 1
study from Australia [30], and 1 study from the UK [31].
A total of 2160 patients in the EGDT group and 2176
patients in the control group were included. Two studies
included patients with severe sepsis and septic shock
who stayed in the intensive care units (ICU) [45, 46],
and the remaining four studies included patients with
severe sepsis and septic shock who presenting to the
emergency department (ED) [6, 7, 30, 31]. All studies
started EGDT for resuscitation within 6 h. The detailed
characteristics of individual eligible study are listed in
Table 1.
Fig. 1 Flow chart for study selection
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Table 1 Characteristics of included studies in the meta-analysis
Study/Year Country Setting No. of patients Resuscitation goals Outcomea
Intervention Control Intervention Control
Rivers [7]/2001 America Eemergency department 130 133 SvO2 ≥ 70 % CVP 8–12 mmHg







Wang [45]/2006 China ICU 16 17 SvO2 ≥ 70 % CVP 8–12 mmHg






Yan [46]/2010 China ICU 157 146 ScvO2 ≥ 70 % CVP 8–12 mmHg
SBP >90 mmHg MAP








ProCESS [6]/2014 America Eemergency department 439 456 ScvO2 ≥ 70 % CVP 8–12 mmHg
MAP 65–90 mmHg
Urine volume ≥0.5 ml/kg/h
Usual care Hospital mortality
ARISE [30]/2014 Australia/New Zealand Eemergency department 793 798 SpO2 ≥ 93 % ScvO2 ≥ 70 % CVP
(Self-ventilation) >8 CVP
(Non-invasive/invasive MV)
>12 mmHgMAP 65–90 mmHg
Urine volume ≥0.6 ml/kg/h
Haematocrit ≥30 %
Usual care 90 days mortality
ProMISe [31]/2015 UK Eemergency department 625 626 ScvO2 ≥ 70 % CVP 8–12 mmHg
MAP 65–90 mmHg Urine volume
≥0.5 ml/kg/h
Usual care 90 days mortality



















Four included studies were rated as low risk of bias
[6, 7, 30, 31] and the remaining studies were rated as
unclear risk of bias due to the insufficiency of defini-
tive describe of randomization and allocation conceal-
ment [45, 46]. The methodological qualities of all
included studies are presented in Fig. 2.
Primary outcome: mortality
The mortality of patients in the standard EGDT group
was 24.2 (522/2160) and the mortality rate of patients in
the usual care group was 25.7 % (559/2176) [6, 7, 30, 31,
45, 46]. The pooled results indicated that, there was no
significant difference in overall mortality rate between
study group and control group, and the pooled odds ra-
tio was 0.83 (95 % confident interval, CI, 0.64–1.08) in
the random-effect model, and 0.91 (95 % CI, 0.79–1.05)
in the fixed effect model. However, there was significant
heterogeneity between studies (p = 0.02, I2 = 64 %)
(Fig. 3). What should be noted here was that the average
mortality rate of the ProCESS, ARISE, and ProMISe
studies [6, 30, 31] was significantly lower than other old
studies (22.2 % vs 48 %) [7, 45, 46]. In a post hoc sub-
group analysis of these three RCTs [6, 30, 31], the effi-
cacy of EGDT compared with usual care was 1.03 (95 %
CI, 0.89–1.21) in the fixed effect model, with no hetero-
geneity (p = 0.78, I2 = 0 %) (Fig. 3). On the contrary, the
pooled OR of the remaining old studies was 0.52 (95 %
CI, 0.37–0.73) in the fixed effect model, with no hetero-
geneity (p = 1.0, I2 = 0 %) (Fig. 3).
TSA was performed for all 6 studies and 3 homoge-
neous RCTs (ProCESS, ARISE, and ProMISe). In the
former analysis, TSA showed that the diversity adjusted
information size was 7536 and the cumulative Z-curve
both did not surpassed the conventional boundary and
trial sequential monitoring boundary for benefit or harm,
as well as did not achieve the optimal information size
which indicated the current results were not robust, and
further clinical trials were required. However, the above
results of TSA were gained based on 6 studies with signifi-
cant heterogeneity (Fig. 4). The TSA of 3 homogeneous
RCTs showed the diversity adjusted information size was
2457 and the cumulative Z-curve did not surpassed the
conventional boundary and the trial sequential monitoring
boundary for benefit or harm, but achieved the optimal in-
formation size which indicated the current results were
robust, namely there was no significant difference in mor-
tality between the two groups (Fig. 5).
Additionally, as mortality rates at different follow-up
time-points were reported in each included study, we
pooled these results separately and found there was also
no significant difference in ICU-mortality (OR 0.68 95 CI,
0.44–1.06), hospital mortality (OR 0.85 95 CI, 0.61–1.17),
28-day mortality (OR 0.72, 95 CI, 0.51–1.04), 60 mortality
(OR 0.82, 95 CI, 0.41–1.64) and 90-day mortality (OR
0.98, 95 % CI, 0.84–1.14) (see Additional file 2) between
two groups.
Secondary endpoint-1: length of stay in the ED, ICU, and
hospital
The ED-LOS, ICU-LOS and hospital-LOS were reported
as median and interquartile range in some studies, which
might limit the quantitatively pool of results (Table 2).
ED-LOS was reported in the study by Yan [46] and the
ARISE and ProMISe studies [30, 31]. In the ARISE
study, the authors reported that EGDT was associated
with shorter ED time, however, this effect of EGDT was
not found in Yan’s study and the ProMISe study [30].
ICU-LOS was reported in the ProCESS, ARISE and
ProMISe studies [6, 30, 31]. And the pooled results
showed that there was no effect of EGDT on ICU-LOS
(MD 0.05, 95%CI −0.43 - 0.53) with no significant het-
erogeneity (I2 = 17 %, p = 0.3) (see Additional file 3).
Hospital-LOS was reported in the study by Rivers and
the ProCESS, ARISE and ProMISe studies [6, 7, 30, 31].
The pooled results showed there was also no effect of
Fig. 2 Risk of bias summary
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EGDT on hospital-LOS (MD −0.07, 95%CI −1.12 - 0.97)
with no heterogeneity (I2 = 0 %, p = 0.73). (see Additional
file 4). After removing the study by Rivers [7], the pooled
results was −0.11 (95%CI −1.21 - 1.00), with no hetero-
geneity (I2 = 0 %, p = 0.53).
Secondary endpoint-2: mechanical ventilation rate, renal
replacement therapy rate and ICU admission
Four studies [6, 7, 30, 31] reported data on mechanical
ventilation rate, and the pooled results showed that there
was no difference in mechanical ventilation rate between
the two groups (OR 1.00, 95%CI 0.87 - 1.14) with moder-
ate heterogeneity (I2 = 63 %, p = 0.04) (Table 3, Additional
file 5). After removing the study by Rivers [7], the pooled
OR was 1.04 (95%CI 0.91–1.20), with no significant het-
erogeneity (I2 = 37 %, p = 0.2).
Three studies [6, 30, 31] reported data on renal replace-
ment therapy rate, and the pooled results showed that
there was no difference in renal replacement therapy rate
between the two groups (OR 1.04, 95%CI 0.84, 1.28) with
no heterogeneity (I2 = 0 %, p = 0.88) (see Additional file 6).
Additionally, EGDT was associated with more ICU
admissions, and the pooled OR was 2.21 (95%CI 1.83 -
2.68), with no significant heterogeneity (P = 0.32; I2 =
13 %) (see Additional file 7).
Secondary endpoint-3: intravenous fluids volume (ml),
vasopressor use rate, dobutamine use rate and blood
transfusion rate from 0 to 72 h
The intravenous fluids volume was reported in five stud-
ies [6, 7, 30, 31, 45] (Table 4). During the 6-h interven-
tion period, patients in the EGDT group received a
larger mean volume of intravenous fluids than did those
in the control group (Table 3). Between 6 and 72 h, the
pooled results of the ProCESS, ARISE and ProMISe
studies [6, 30, 31] showed that there was no significant
difference in intravenous fluids volume between the two
groups. Between 0 and 72 h, it was seemed that patients
in the EGDT group received more intravenous fluids
than those in the usual care group. However, the pooled
results of the ProCESS and ProMISe studies [6, 31]
showed that there was no statistical significance between
the two groups (see Additional file 8).
The results of vasopressor use rates were showed in
Table 4. The pooled results showed that more patients
in the EGDT group received vasopressor in the first 6 h
(OR 1.38, 95%CI 1.19–1.60), with no significant hetero-
geneity (I2 = 20 %, p = 0.29); From 6 to 72 h and 0 to
72 h, the pooled results showed that there was no sig-
nificant difference in vasopressor use rate between the
two groups, however, with significant heterogeneity (I2 =
68 and I2 = 78 %, separately). After removing the study
by Rivers [7], the pooled results showed that EGDT was
associated with a higher vasopressor use rate (0–6 h: OR
1.42, 95%CI 1.25–1.62; 6–72 h: OR 1.27, 95 % 1.12–1.45;
0–72 h: OR 1.28 95%CI 1.08–1.52), with no heterogen-
eity (I2 = 0 %, p = 0.62; I2 = 0 %, p = 0.76; I2 = 0 %, p =
0.79, separately) (see Additional file 9).
The results of dobutamine usage rate were also
showed in Table 4. The pooled results showed that
EGDT was associated with a higher dobutamine usage
rate (0–6 h: OR 6.68, 95%CI 4.91 - 9.10; 6–72 h: OR
2.41 95%CI 1.88–3.09; 0–72 h: OR 3.40 95%CI 2.54–
4.54), with no significant heterogeneity (I2 = 0 %, p =
0.55; I2 = 3 %, p = 0.38; I2 = 30 %, p = 0.24, separately).
After removing the study by Rivers [7], the pooled re-
sults did not change a lot (0–6 h: OR 6.43, 95%CI 4.70 -
8.80; 6–72 h: OR 2.47 95%CI 1.91 - 3.21; 0–72 h: OR
Fig. 3 Forest plot showing the effects of early goal-direced therapy on all-cause mortality in patients with severe sepsis and septic shock
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3.72 95%CI 2.72 - 5.09), with no significant heterogen-
eity (I2 = 0 %, p = 0.59; I2 = 26 %, p = 0.26; I2 = 0 %, p =
0.84, separately) (see Additional file 10).
Table 4 showed the results of transfusion rate. The
pooled results showed that patients in the EGDT
group received more blood transfusion than those in
the control group in the first 6 h and between 0 and
72 h (OR 2.91, 95%CI 1.72 - 4.91; OR 1.75, 95%CI
1.21–2.54, separately), with significant heterogeneity
(I2 = 81 %, p = 0.001; I2 = 65 %, p = 0.06). However, the
above effect of EGDT was not found between 6 and
72 h (OR 0.87, 95%CI 0.51–1.46) with significant het-
erogeneity (I2 = 86 %, p = 0.0001). After removing the
study by Rivers [7], the pooled results did not change
a lot (0–6 h: OR 2.16, 95%CI 1.71 - 2.73; 6–72 h: OR
1.16 95%CI 0.86 - 1.55; 0–72 h: OR 1.52 95%CI 1.12 -
2.06), with no significant heterogeneity (I2 = 0 %,
p = 0.87; I2 = 56 %, p = 0.11; I2 = 47 %, p = 0.17, separately)
(see Additional file 11).
Secondary endpoint-4: adverse events
The incidences of adverse events were reported in 3
studies [6, 30, 31]. The pooled results showed that there
were no effects of EGDT on the incidence of adverse
events (OR 1.06, 95%CI 0.80 - 1.39) with moderate het-
erogeneity (I2 = 62 %, p = 0.07) (see Additional file 12).
Discussion
Six studies were identified from 2001 to 2015 enrolling a
total of 4336 patients [6, 7, 30, 31, 45, 46]. The present
meta-analysis showed that there was no difference in
mortality rate of patients between the EGDT group and
the usual care group. Furthermore, the results of TSA
Fig. 4 Trial sequential analysis of all-cause mortality in patients with severe sepsis and septic shock. Trial sequential analyses assessing the effect
of early goal-direced therapy on all-cause mortality in 6 studies. The diversity-adjusted required information size was based on a relative risk reduction
of 20; an alpha of 5; a beta of 2 and an event proportion of 25.7 % in the control arm. The blue cumulative z curve was constructed using a random
effects model
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indicated that the present conclusion was robust, and no
further studies were required.
Although our results showed that the application of
EGDT could not reduce the mortality rate of patients
with severe sepsis and septic shock, one of the most
plausible explanations for the decline in mortality trends
in recent years was the practice of EGDT [47, 48]. The
following reasons may explain these inconsistencies. Due
to the appealing results of the study by Rivers, EGDT
gets the recommendation of the SSC guideline, and has
been regarded as the standard of care in patients with
severe sepsis and septic shock in many hospitals in de-
veloped areas [7]. As in the ARISE study [30], There was
no significant difference in the mean intravenous fluid
volume that had been infused prior to randomization,
61.9 % of patients in the usual-care group received cen-
tral venous catheter insertion and the time of initial use
of intravenous antimicrobial was similar between the
two groups. Similar situation was also present in the
ProCESS study [6] and ProMISe study [31]. That is, the
essence of EGDT (early identification and diagnosis of
sepsis, early fluid resuscitation and early infection con-
trol) has been penetrated into the standard of care in pa-
tients with severe sepsis and septic shock, that is why
the mortality rates of patients in the ProCESS, ARISE
and ProMISe [6, 30, 31] studies were significantly lower
than those in the study by Rivers [7]. Here, it should be
noted that the newest 3 RCTs were conducted in devel-
oped areas (one in America [6], one in Australia [30]
and one in the UK [31]). In the study by Zhu [49], the
Fig. 5 Trial sequential analysis of all-cause mortality in patients with severe sepsis and septic shock of ProCESS, ARISE and ProMISe. Trial sequential
analyses assessing the effect of early goal-direced therapy on all-cause mortality in 3 multicenter harmonious studies. The diversity-adjusted required
information size was based on a relative risk reduction of 20; an alpha of 5; a beta of 2 and an event proportion of 22.2 %in the control arm. The blue
cumulative z curve was constructed using a random effects model
Table 2 Characteristics of included studies on ED-LOS/ICU-LOS/Hospital-LOS
ED-LOS ICU-LOS Hospital-LOS
Author EGDT Usual care P EGDT Usual care P EGDT Usual care P
Yan [45] 19.9 ± 2.2a 20.6 ± 1.9a 0.82 NA NA NA NA NA NA
Rivers [7] NA NA NA NA NA NA 13.2 ± 13.8a 13 ± 13.7a 0.54
ProCESS [6] NA NA NA 5.1 ± 6.3a 4.7 ± 5.8a 0.63 11.1 ± 10a 11.3 ± 10.9a 0.25
ARISE [30] 1.4 (0.5–2.7)b 2.0 (1.0–3.8)b 0.001 2.8 (1.4–5.1)b 2.8 (1.5–5.7)b 0.81 8.2 (4.9–16.7)b 8.5 (4.9–16.5)b 0.89
ProMISe [31] 1.5 (0.4–3.1) b 1.3 (0.4–2.9)b 0.34 2.6 (1.0–5.8)b 2.2 (0.0–5.3)b 0.005 9 (4–21)b 9 (4–18) b 0.46
LOS length of stay, ED emergency department, ICU intensive care unit, NA no available, P P value
amean ± standard deviation; bmedian(interquartile range)
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authors examined the compliance of the SSC resuscita-
tion bundle in patients presenting to the emergency de-
partment with severe sepsis and septic shock in a
university affiliated hospital in China. The results
showed all elements of the bundle were completed in
only 1.04 % of patients, and this number was signifi-
cantly lower than that in the developed areas [50]. An-
other study also pointed out that the rate of compliance
with resuscitation bundle in Asia was significantly lower
than that in the Europe and America [51, 52]. In general,
factors hindering clinicians from adhering to clinical
practice guidelines include knowledge, attitude and be-
havior. Firstly, the imperfect understanding of the defin-
ition of severe sepsis and septic shock limits the early
diagnosis of these serious conditions [49]. Secondly, in-
sufficient training of sepsis resuscitation bundle further
limits the practice of the EGDT [50, 52]. Thirdly, as the
doctor-patient contradiction is aggravating gradually es-
pecially in China, more and more severe sepsis patients
are hospitalized directly, instead of receiving standard
resuscitation following the SSC guideline in the emer-
gency department [53]. Fourthly, the practice of EGDT
is resource-intensive. Given the insufficient number of
medical staffs and disproportionate emergency visits, the
application of EGDT would significantly prolong the stay in
the emergency department. Meanwhile, other patients
could not receive timely and effective treatment [53, 54]. Fi-
nally, in some low and middle income nations, blood
Table 3 Characteristics of included studies on mechanical ventilation/renal replacement therapy/ICU admission
Mechanical ventilation Renal replacement therapy ICU admission
Author EGDT Usual care P EGDT Usual care P EGDT Usual care P
Rivers [7] 65/130 84/133 0.02 NA NA NA NA NA NA
ProCESS [6] 165/434 146/451 NA 12/382 11/397 NA 401/439 393/456 0.01
ARISE [30] 238/793 251/798 0.52 106/793 108/798 0.94 725/793 661/798 NA
ProMISe [31] 179/620 175/615 0.9 88/620 81/614 0.62 551/625 467/626 NA
ICU intensive care unit, NA no available, P P value
Table 4 Resuscitation and processes of care from baseline to 72 h
0–6 h 6–72 h 0–72 h
Author EGDT Usual care P EGDT Usual care P EGDT Usual care P
Wang [45] Intravenous fluids
(ml)
4895 ± 210a 2340 ± 95a 0.01 NA NA NA NA NA NA
Rivers [7] Intravenous fluids
(ml)
4981 ± 2984a 3499 ± 2438a 0.001 8625 ± 5162a 10602 ± 6216a 0.01 13443 ± 6390a 13358 ± 7729a 0.73
Vasopressor use 32/117 36/119 0.62 34/117 51/119 0.03 43/117 61/119 0.02
Dobutamine use 16/117 1/119 0.001 17/117 10/119 0.14 18/117 11/119 0.15
Blood transfusion 75/117 22/119 0.001 13/117 39/119 0.001 80/117 53/119 0.001
ProCESS [6] Intravenous fluids
(ml)
2805 ± 1957a 2279 ± 1881a 0.0001 4458 ± 3878a 4354 ± 3882a 0.08 7253 ± 4605a 6633 ± 4560a 0.0001
Vasopressor use 241/439 201/456 0.003 209/439 197/456 0.38 265/439 245/456 0.05
Dobutamine use 35/439 4/456 0.0001 19/439 10/456 0.08 41/439 13/456 0.0001
Blood transfusion 63/439 34/456 0.001 87/439 82/456 0.54 120/439 102/456 0.22
ARISE [30] Intravenous fluids
(ml)
1964 ± 1415a 1713 ± 1401a 0.001 4274 ± 3071a 4382 ± 3136a 0.51 NA NA NA
Vasopressor use 528/793 461/798 0.001 460/782 401/778 0.004 NA NA NA
Dobutamine use 122/793 21/798 0.001 74/782 39/788 0.001 NA NA NA
Blood transfusion 108/793 56/798 0.001 86/782 92/778 0.61 NA NA NA
ProMISe [31] Intravenous fluids
(ml)
2226 ± 1443a 2022 ± 1271 NA 4215 ± 3068a 4366 ± 3114 NA 5946 ± 3740a 5844 ± 3651a NA
Vasopressor use 332/623 291/625 NA 349/603 317/603 NA 377/623 344/625 NA
Dobut mine use 113/623 24/625 NA 107/603 39/603 NA 139/623 44/625 NA
Blood transfusion 55/623 24/625 NA 76/603 51/603 NA 107/623 65/625 NA
NA no available, P P value
amean ± standard deviation
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culture, central venous pressure or blood gases measure-
ment, lactate and central or mixed venous oxygen satur-
ation measurement could not be performed directly in
emergency department even in intensive care units [49, 52].
Therefore, the results of the 3 newest RCTs [6, 30, 31] do
not indicate that there is no effect of EGDT on mortality
rate in patients with severe sepsis and septic shock. Instead,
their findings suggest the EGDT has been regarded as the
standard of care in these patients particularly in developed
areas. And further studies evaluating EGDT versus usual
care in patients with severe sepsis and septic shock in low
or moderate countries may be required.
In recent year, several meta-analysis reported that EGDT
was associated with lower risk of mortality in patients with
severe sepsis and septic shock [32, 55–57]. However, the
rates of compliance with the SSC guideline were low in
these meta-analysis, indicating that the drop in mortality is
partially due to other factors. Additionally, EGDT is more
capable in correcting cryptogenic shock by continuous
monitoring of ScvO2. However, its effectiveness has been a
topic of much debate and many other indicators which are
more cost-effective has been proposed, including lactate
concentration, base deficit, and pH [58]. In a recent study,
the authors concluded that fluid resuscitation therapy
under the guidance of lactate concentration rate was feas-
ible and reliable in patients with severe sepsis and septic
shock [59]. Furthermore, it has been reported that early
lactate-guided therapy was associated with lower mortality
rate in patients with severe sepsis and septic shock [60]. In
addition, the effectiveness of CVP was also questioned in a
retrospective study [61]. Excessive medical treatment is as-
sociated with unfavorable outcomes [62]. Therefore, the
concept of “one size fits all” is not appropriate for a com-
plex disease state like severe sepsis or septic shock, and the
new concept of “individualized goal-directed hemodynamic
therapy” has been proposed [63].
Strengths and limitations
To our best knowledge, the present meta-analysis was the
first to systematically evaluating the standard EGDT versus
usual care in patients with severe sepsis and septic shock
with TSA. Three multicenter RCTs (ProCESS, ARISE and
ProMISe) were included [6, 30, 31]. Our search strategy
was broad and irrespective of language. The study selection,
data extraction and methodological evaluation were rigor-
ously performed by two investigators independently. An-
other advantage of our meta-analysis was TSA. The last but
not least was that we prospectively registered our study
protocol with PROSPERO (International prospective regis-
ter of systematic reviews; CRD42015017667).
However, several limitations of our meta-analysis should
be mentioned. Firstly, some studies evaluating modified
EGDT were not included. Secondly, the organizational
structures of EDs or ICUs, demographic characteristics of
sepsis patients, and the definitions of usual cares may be
different in different areas. Thirdly, SOFA-score which
was a secondary endpoint in our registered protocol was
replaced by length of stay in emergency department,
mechanical ventilation rate, renal replacement therapy
rate and the incidence of adverse events in the present
meta-analysis. Finally, the number of included studies was
too small to perform publication bias examination; there-
fore our results may be influenced by the publication bias.
Conclusions
The current evidence does not support the significant
advantage of early goal-directed therapy (EGDT) in the
resuscitation of patients with severe sepsis and septic
shock. Despite the conclusion of the present meta-
analysis was robust in developed areas, more designed
rigorously studies are required to determine the effects
of EGDT on patients with severe sepsis and septic shock
in low and moderate income areas.
Additional files
Additional file 1: Forest plot showing the effects of early goal-direced
therapy on ICU, hospital, 28-day, 60-day and 90-day mortality. (DOC 20 kb)
Additional file 2: Forest plot showing the effects of early goal-direced
therapy on length of ICU stay. (TIF 1379 kb)
Additional file 3: Forest plot showing the effects of early goal-direced
therapy on length of hospital stay. (TIF 352 kb)
Additional file 4: Forest plot showing the effects of early goal-direced
therapy on mechnical ventilation rate. (TIF 209 kb)
Additional file 5: Forest plot showing the effects of early goal-direced
therapy on renal replacement therapy rate. (TIF 408 kb)
Additional file 6: Forest plot showing the effects of early goal-direced
therapy on ICU admission rate. (TIF 367 kb)
Additional file 7: Forest plot showing the effects of early goal-direced
therapy on intraveous fluids volumes. (TIF 375 kb)
Additional file 8: Forest plot showing the effects of early goal-direced
therapy on vasopressor use rate. (TIF 968 kb)
Additional file 9: Forest plot showing the effects of early goal-direced
therapy on dobutamine usage rate. (TIF 942 kb)
Additional file 10: Forest plot showing the effects of early goal-direced
therapy on blood transfusion rate. (TIF 946 kb)
Additional file 11: Forest plot showing the effects of early goal-direced
therapy on adverse events. (TIF 939 kb)
Additional file 12: Search strategy (Pubmed). (TIF 369 kb)
Abbreviations
CI: confidence interval; EGDT: early goal-directed therapy; ICU: intensive care
unit; LOS: length of stay; MV: mechanical ventilation; OR: odd ratio;
RCT: randomised controlled trial; ScvO2: central venous oxygen saturation;
TSA: trial sequential analysis; WMD: weighted mean difference.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
ZM, MYF conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. JLB drafted the manuscript.
JSY helped to perform the statistical analysis. All authors read and approved
the final manuscript
Jiang et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:23 Page 10 of 12
Acknowledgments




Received: 15 September 2015 Accepted: 27 February 2016
References
1. Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the
burden of sepsis: global estimates of incidence, prevalence and mortality.
J Glob Health. 2012;2:010404.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR.
Epidemiology of severe sepsis in the United States: analysis of incidence,
outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.
3. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and
mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167–74.
4. The Australasian Resuscitation in Sepsis Evaluation (ARISE) Investigators,
Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient
Database (APD) Management Committee. The outcome of sepsis and septic
shock presenting to the emergency departments of Australia and New
Zealand. Crit Care Resusc. 2007;9:8–18.
5. Quenot JP, Binquet C, Kara F, Martinet O, Ganster F, Navellou JC, et al. The
epidemiology of septic shock in French intensive care units: the prospective
multicenter cohort EPISS study. Crit Care. 2013;17:R65.
6. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, et al. A
randomized trial of protocol-based care for early septic shock. N Engl J
Med. 2014;370:1683–93.
7. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early
goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med. 2001;345:1368–77.
8. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.
Surviving Sepsis Campaign: international guidelines for management of severe
sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.
9. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al.
Surviving Sepsis Campaign: international guidelines for management of
severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296–327.
10. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al.
Surviving Sepsis Campaign guidelines for management of severe sepsis and
septic shock. Crit Care Med. 2004;32(3):858–73.
11. Micek ST, Roubinian N, Heuring T, Bode M, Williams J, Harrison C, et al.
Before-after study of a standardized hospital order set for the management
of septic shock. Crit Care Med. 2006;34:2707–13.
12. Nguyen HB, Corbett SW, Steele R, Banta J, Clark RT, Hayes SR, et al.
Implementation of a bundle of quality indicators for the early management
of severe sepsis and septic shock is associated with decreased mortality. Crit
Care Med. 2007;35:1105–12.
13. Trzeciak S, Dellinger RP, Abate NL, Cowan RM, Stauss M, Kilgannon JH, et al.
Translating research to clinical practice: a 1-year experience with
implementing early goal-directed therapy for septic shock in the
emergency department. Chest. 2006;129:225–32.
14. Shapiro NI, Howell MD, Talmor D, Lahey D, Ngo L, Buras J, et al.
Implementation and outcomes of the Multiple Urgent Sepsis Therapies
(MUST) protocol. Crit Care Med. 2006;34:1025–32.
15. Kortgen A, Niederprum P, Bauer M. Implementation of an evidence-based
“standard operating procedure” and outcome in septic shock. Crit Care
Med. 2006;34:943–9.
16. El Solh AA, Akinnusi ME, Alsawalha LN, Pineda LA. Outcome of septic shock
in older adults after implementation of the sepsis “bundle”. J Am Geriatr
Soc. 2008;56:272–8.
17. Sebat F, Johnson D, Musthafa AA, Watnik M, Moore S, Henry K, et al. A
multidisciplinary community hospital program for early and rapid
resuscitation of shock in nontrauma patients. Chest. 2005;127:1729–43.
18. Jones AE, Focht A, Horton JM, Kline JA. Prospective external validation of the
clinical effectiveness of an emergency department-based early goal-directed
therapy protocol for severe sepsis and septic shock. Chest. 2007;132:425–32.
19. Girardis M, Rinaldi L, Donno L, Marietta M, Codeluppi M, Marchegiano P,
et al. Sopravvivere alla Sepsi Group of the Modena-University Hospital:
Effects on management and outcome of severe sepsis and septic shock
patients admitted to the intensive care unit after implementation of a
sepsis program: a pilot study. Crit Care. 2009;13:R143.
20. Castellanos-Ortega A, Suberviola B, García-Astudillo LA, Holanda MS, Ortiz F,
Llorca J, et al. Impact of the Surviving Sepsis Campaign protocols on hospital
length of stay and mortality in septic shock patients: results of a three-year
follow-up quasi-experimental study. Crit Care Med. 2010;38:1036–43.
21. Levy MM, Rhodes A, Phillips GS, Townsend SR, Schorr CA, Beale R, et al.
Surviving Sepsis Campaign: association between performance metrics and
outcomes in a 7.5-year study. Crit Care Med. 2015;43(1):3–12.
22. Ferrer R, Artigas A, Levy MM, Blanco J, González-Díaz G, Garnacho-Montero
J, et al. Improvement in process of care and outcome after a multicenter
severe sepsis educational program in Spain. JAMA. 2008;299:2294–303.
23. Shin HJ, Kang HL, Hwang SO, Kim H, Shin TY, Sang CK, et al. The efficacy of
early goal-directed therapy in septic shock patients in the emergency
department: severe sepsis campaign. Korean J Critic Care Med. 2010; 25(2):61-70.
24. Pestaña D, Espinosa E, Sangüesa-Molina JR, Ramos R, Pérez-Fernández E,
Duque M, et al. Compliance with a sepsis bundle and its effect on intensive
care unit mortality in surgical septic shock patients. J Trauma. 2010;69:1282–7.
25. Miller 3rd RR, Dong L, Nelson NC, Brown SM, Kuttler KG, Probst DR, et al.
Intermountain Healthcare Intensive Medicine Clinical Program: Multicenter
implementation of a severe sepsis and septic shock treatment bundle. Am J
Respir Crit Care Med. 2013;188:77–82.
26. Heppner HJ, Singler K, Kwetkat A, Popp S, Esslinger AS, Bahrmann P, et al.
Do clinical guidelines improve management of sepsis in critically ill elderly
patients? A before-and-after study of the implementation of a sepsis
protocol. Wien Klin Wochenschr. 2012;124:692–8.
27. Gao F, Melody T, Daniels DF, Giles S, Fox S. The impact of compliance with
6-h and 24-h sepsis bundles on hospital mortality in patients with severe
sepsis: a prospective observational study. Crit Care. 2005;9:R764–70.
28. Lefrant JY, Muller L, Raillard A, Jung B, Beaudroit L, Favier L, et al. Reduction
of the severe sepsis or septic shock associated mortality by reinforcement
of the recommendations bundle: a multicenter study. Ann Fr Anesth
Reanim. 2010;29:621–8.
29. Cardoso T, Carneiro AH, Ribeiro O, Teixeira-Pinto A, Costa-Pereira A.
Reducing mortality in severe sepsis with the implementation of a core 6-h
bundle: results from the Portuguese community-acquired sepsis study
(SACiUCI study). Crit Care. 2010;14:R83.
30. Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, et al.
Goal-directed resuscitation for patients with early septic shock. N Engl J
Med. 2014;371(16):1496–506.
31. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD,
et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J
Med. 2015;372(14):1301–11.
32. Gu WJ, Wang F, Bakker J, Tang L, Liu JC. The effect of goal-directed therapy
on mortality in patients with sepsis - earlier is better: a meta-analysis of
randomized controlled trials. Crit Care. 2014;18(5):570.
33. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ. 2009;339:b2535.
34. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al.
American College of Chest Physicians/Society of Critical Care Medicine.
Chest. 1992;101:1644–55.
35. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.
Crit Care Med. 2003;31(4):1250–6.
36. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0. Oxford: The Cochrane Collaboration; 2011.
37. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The
Cochrane Collaboration’s tool for assessing risk of bias in randomized trials.
BMJ. 2011;343:d5928.
38. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21:1539–58.
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ. 2003;327:557–60.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7:177–88.
41. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315:629–34.
42. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals
insufficient information size and potentially false positive results in many
meta-analyses. J Clin Epidemiol. 2008;61:763–9.
Jiang et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:23 Page 11 of 12
43. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information
size by quantifying diversity in random-effects model meta-analyses. BMC
Med Res Methodol. 2009;9:86.
44. Jiang L, Jiang S, Zhang M, Zheng Z, Ma Y. Albumin versus other fluids for
fluid resuscitation in patients with sepsis: a meta-analysis. PLoS One.
2014;9(12):e114666.
45. Wang XZ, Lü CJ, Gao FQ, Li XH, Yan WF, Ning FY. Efficacy of goal-directed
therapy in the treatment of septic shock. Zhongguo Wei Zhong Bing Ji Jiu
Yi Xue. 2006;18:661–4.
46. Early Goal-Directed Therapy Collaborative Group of Zhejiang Province. The
effect of early goal-directed therapy on treatment of critical patients with
severe sepsis/septic shock: a multi-center, prospective, randomized,
controlled study. ZhongguoWei Zhong Bing Ji Jiu Yi Xue. 2010;22:331–4.
47. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK.
Hospitalizations, costs, and outcomes of severe sepsis in the United States
2003 to 2007. Crit Care Med. 2012;40:754–61.
48. Muck A, Adams BD. ACP journal club. Early goal-directed therapy did not
reduce mortality more than usual care in early septic shock. Ann Intern
Med. 2015;162(6):JC4.
49. Zhu Y, Tao RJ, Shi W, Tong JJ, Lu YM. A study of rate of compliance with
sepsis bundle in patients with severe sepsis and septic shock in emergency
department. Chin Crit Care Med. 2011;23:138–41.
50. Nguyen HB, Lynch EL, Mou JA, Lyon K, Wittlake WA, Corbett SW. The utility
of a quality improvement bundle in bridging the gap between research
and standard care in the management of severe sepsis and septic shock in
the emergency department. Acad Emerg Med. 2007;14:1079–86.
51. Na S, Kuan WS, Mahadevan M, Li CH, Shrikhande P, Ray S, et al. Implementation
of early goal-directed therapy and the surviving sepsis campaign resuscitation
bundle in Asia. Int J Qual Health Care. 2012;24(5):452–62.
52. Phua J, Koh Y, Du B, Tang YQ, Divatia JV, Tan CC, et al. Management of
severe sepsis in patients admitted to Asian intensive care units: prospective
cohort study. BMJ. 2011;342:d3245.
53. Yin M, Meng XK, Zheng XY, Xiong LH, Zhou D, Zhang XH, et al. The
implementation of early goal-directed therapy of patients with severe sepsis
and septic shock in China: a multi-center study. The ninth army emergency
medicine academic conference proceedings. 2011. p. 161–4.
54. Zhao L, Xiao B, Liu CL, Wang XY, Li B, Du XX. Establishment and application
of the number of outpatient and emergence visits and discharged patients
prediction linear regression model. Chinese Medical Record. 2014;11:39–40.
55. Wira CR, Dodge K, Sather J, Dziura J. Meta-analysis of protocolized goal-
directed hemodynamic optimization for the management of severe sepsis and
septic shock in the emergency department. West J Emerg Med. 2014;15:51–9.
56. Chamberlain DJ, Willis EM, Bersten AB. The severe sepsis bundles as
processes of care: a meta-analysis. Aust Crit Care. 2011;24:229–43.
57. Barochia AV, Cui X, Vitberg D, Suffredini AF, O’Grady NP, Banks SM, et al. Bundled
care for septic shock: analysis of clinical trials. Crit Care Med. 2010;38:668–78.
58. Elliott DC. An evaluation of the end points of resuscitation. J Am Coll Surg.
1998;187:536–47.
59. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA. Lactate
clearance vs central venous oxygen saturation as goals of early sepsis
therapy: a randomized clinical trial. JAMA. 2010;303:739–46.
60. Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der
Klooster JM, Lima AP, et al. Early lactate-guided therapy in intensive care
unit patients: a multicenter, open-label, randomized controlled trial. Am J
Respir Crit Care Med. 2010;182:752–61.
61. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, et al.
Association between systemic hemodynamics and septic acute kidney
injury in critically ill patients: a retrospective observational study. Crit Care.
2013;17:R278.
62. Chen C, Kollef MH. Conservative fluid therapy in septic shock: an example of
targeted therapeutic minimization. Crit Care. 2014;18(4):481.
63. Saugel B, Trepte CJ, Heckel K, Wagner JY, Reuter DA. Hemodynamic
Management of Septic Shock: Is It Time for “Individualized Goal-Directed
Hemodynamic Therapy” and for Specifically Targeting the Microcirculation?
Shock. 2015;43(6):522–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Jiang et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:23 Page 12 of 12
